A recent drug trial conducted on a handful of cancer patients had the surprising result that the disease was wiped out in every participant.
The study was conducted on 18 patients with rectal cancer at the Memorial Sloan Kettering Cancer Center in Manhattan and had a 100 percent success rate, according to an article published Sunday in the New England Journal of Medicine.
“I believe this is the first time in the history of cancer,” said Dr. Luis A. Diaz Jr., the author of the study, The New York Times.
The drug dostarlimab was administered to each patient every 3 weeks for 6 months.
It was expected that the drug study would be followed by chemotherapy and surgery as usual for each participant.
Some patients may even have needed surgery, leading to bowel and urinary dysfunction — or be forced to use a colostomy bag because of the treatment, the Times said.
However, because all patients had no evidence of a tumor by MRI, rectal examination, or biopsy, they were spared the agony of potentially harmful treatment.
“There were many tears of joy,” said Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center, told the Times.
Aside from requiring no further treatment, patients did not experience cancer recurrence during follow-up visits ranging from 6 to 25 months after the end of the study.
One participant, Sascha Roth, told the Times she plans to move to Manhattan for chemotherapy and radiation.
Then the doctors gave her the good news—the study worked and she was cancer-free.
“I told my family,” Roth said. “You didn’t believe me.”
https://nypost.com/2022/06/06/every-cancer-patient-enters-remission-after-drug-trial/ Every cancer patient enters remission after a drug trial